September 17, 2015
Eli Lilly Japan’s once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist Trulicity Subcutaneous Injection 0.75 mg Ateos (recombinant dulaglutide) went on sale on September 16. Lilly holds the marketing authorization for the type 2 diabetes drug, while its partner Sumitomo Dainippon Pharma...read more